Fuan Pharmaceutical Group Co

Fuan Pharmaceutical Group announced that its wholly-owned subsidiary, Fuan Pharmaceutical Group Qingyutang Pharmaceutical, has received a Drug Registration Certificate from the National Medical Products Administration for injectable lysine acetylsalicylate, which is deemed to have passed the consistency evaluation. The approved specifications are 0.5 grams and 0.9 grams, with a registration classification of chemical drug category 3, and approval numbers Guo Yao Zhun Zi H20265919 and H20265920 respectively. Injectable lysine acetylsalicylate is indicated for the treatment of fever and moderate pain when oral administration is not suitable. According to the National Medical Products Administration data query platform, as of now, a total of 11 companies, including Qingyutang, have passed or are deemed to have passed the consistency evaluation for this drug. The company stated that obtaining this registration certificate will further enrich the subsidiary's product line and enhance its market competitiveness, but due to factors such as industry policies and changes in the market environment, there is uncertainty regarding the production and sales of the product.

Fuan Pharmaceutical's wholly-owned subsidiary, Fuan Pharmaceutical Group Qingyutang Pharmaceutical Co., Ltd., has received the Drug Registration Certificate for Ceftazidime Avibactam Sodium for Injection issued by the National Medical Products Administration. The drug specification is 2.5 grams, registered as a Category 4 chemical drug, and is deemed to have passed the consistency evaluation. It is indicated for the treatment of complicated intra-abdominal infections, hospital-acquired pneumonia, and ventilator-associated pneumonia, among others. Currently, a total of 22 companies have passed or are deemed to have passed the consistency evaluation for this drug. The company stated that this approval will further enrich the subsidiary's product pipeline, but the impact on performance remains uncertain.

Fuan Pharmaceutical's wholly-owned subsidiary Tianheng Pharmaceutical recently obtained a drug registration certificate for Bromhexine Hydrochloride Injection from the National Medical Products Administration. The drug is registered as a chemical drug Category 3, with a specification of 2ml:4mg, and is indicated for patients with chronic bronchitis and other respiratory diseases who have difficulty expectorating viscous sputum when oral administration is challenging. To date, a total of 30 companies have passed or are deemed to have passed the consistency evaluation for this drug. In the first quarter of 2026, Fuan Pharmaceutical achieved revenue of 407 million yuan and a net profit attributable to the parent company of 54.92 million yuan.